title: Prevalence of phosphodiesterase-5 inhibitor use in the VHA in 2004 and 2005 is twice that of a commercial health plan in 2001.
authors.forename: Dustin D
authors.initials: DD
authors.lastname: French
authors.forename: Curtis E
authors.initials: CE
authors.lastname: Margo
authors.forename: Robert R
authors.initials: RR
authors.lastname: Campbell
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D004363:Drug Utilization; D007172:Erectile Dysfunction / Q000188:drug therapy; D006787:Hospitals, Veterans; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D014481:United States; D014493:United States Department of Veterans Affairs
chemical_list: D010726:Phosphodiesterase Inhibitors; D015106:3',5'-Cyclic-GMP Phosphodiesterases